Everything below concerns Lipodystrophy. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-28. Numbers and descriptions here follow the published literature rather than marketing material.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
=== History === The family Liliaceae was described by Michel Adanson in 1763 and formally named by Antoine Laurent de Jussieu in 1789. Jussieu defined this grouping as having a calyx of six equal colored parts, six stamens, a superior ovary, single style, and a trilocular (three-chambered) capsule. By 1845, John Lindley, the first English systematist, unhappily acknowledged the great diversity in the circumscription of the family, and that it had expanded vastly, with many subdivisions. As he saw it, the Liliaceae were already paraphyletic ("catch-all"), being all Liliales not included in the other families, but hoped that the future would reveal some characteristic that would group them better. He recognized 133 genera and 1200 species. By the time of the next major British classification – that of Bentham and Hooker in 1883 (published in Latin) – several of Lindley's other families had already been absorbed into the Liliaceae. Over time the family became increasingly broad and somewhat arbitrarily defined as all species of plants with six tepals and a superior ovary, eventually coming to encompass about 300 genera and 4,500 species within the order Liliales under the Cronquist system (1981). Cronquist merged the Liliaceae with the Amaryllidaceae, making this one of the largest monocotyledon families. Many other botanists echoed Lindley's earlier concerns about the phylogeny of the Liliaceae, but various schemes to divide the family gained little traction.
Additionally, it reacts with NADPH-dependent acetoacetyl-coenzyme A reductase, also known as PhaB, in a pathway that produces polyester polyhydroxyalkanoate (PHA). The reduction of acetoacetyl-coA by Pha creates (R)-3-hydroxybutyryl-CoA, which polymerizes to PHA. The pathway is present in bacteria such as Ralstonia eutropha and the PCC6803 strain of Synechocystis. Mover over, Acetoacetyl-CoA is involved with neuronal development involving lipogenesis and providing fats and cholesterol for neuronal cells.
Since today's communications have mostly merged into the internet, the Electronic Communications Code Directive 2018 is critical for EU infrastructure. Article 5 requires a member state regulator or a "competent authority" is set up that will license use of the radio spectrum, through which mobile and internet signals travel. A regulator must also enable access and interconnection to other infrastructure (such as telecomms and broadband cables), protect end-user rights, and monitor "competition issues regarding open internet access" to ensure rights such as universal service and portability of phone numbers. Articles 6–8 require the regulators are independent, with dismissal of heads only for a good reason, and articles 10–11 require cooperation with other authorities. Articles 12–13 require that use of electronic communication networks is authorised by a regulator, and that conditions attached are non-discriminatory, proportionate and transparent. The owner of a communication network has duties to allow access and interconnection on fair terms, and so article 17 requires that its accounts and financial reports are separate from other activities (if the enterprise does other business), article 74 foresees that regulators can control prices, and article 84 says member states should "ensure that all consumers in their territories have access at an affordable price, in light of specific national conditions, to an available adequate broadband internet access service and to voice communications services".
==== United Nations Climate Change Conference ==== On 1 November 2022, the COP27 host Egypt invited then President-elect Lula to visit the summit which raised hopes among climate activists and international organizations officials that Brazil will strengthen its environmental policies. Lula accepted the invitation and, while attending the COP27, promised to fight for a zero deforestation in the Amazon and other biomes. He also promised to have a United Nations Climate Change conference held in the Amazon. On 11 January 2023, Lula announced Brazil was making an official bid for the Brazilian city of Belém to host the COP 30. In May 2023, the UN announced that Belém had been chosen to host the summit, a first for a city in the Amazon region. During the COP28, Lula announced that Brazil would join the OPEC+ initiative, which focuses on integration and discussion between members of the group and other countries. He also announced a plan to recover degraded pasturelands, and to boost overall agriculture productivity through loans by Brazil's BNDES.
Sources: en.wikipedia.org
The SPGB does not consider Socialist Studies's position to be incompatible with socialism, but rather simply a different (albeit illogical) interpretation of its principles: Indifference to moves by workers to try to establish a minimum of political democracy has, once again, been a minority position within the SPGB though not a matter for expulsion. If [a companion party] were to adopt this position, we could live with it and would not consider it a matter for its exclusion from the World Socialist Movement (though we would reserve the right to criticise it as illogical).
Dickey, Eddy's private secretary for the last three years of her life, wrote that hour-long watches were held in her home three times a day to protect her against it. The Manual of the Mother Church forbids members from practising it, and requires that Christian Science teachers instruct students "how to defend themselves against mental malpractice, and never to return evil for evil".
==== Idiopathic calcinosis cutis ==== Skin calcification that is not linked to a systemic illness or an underlying tissue injury is referred to as idiopathic calcification. Most often, the calcification is restricted to a single general location, yet there has been one case of calcinosis cutis that is exceptionally broad.
Sources: en.wikipedia.org
This can be especially beneficial in regions with high electrical conductivity or salt content in their water source. This could potentially avoid costly reverse osmosis filtration systems while maintaining high crop yield.
Denazification was an Allied initiative to rid German politics, judiciary, society, culture, press and economy of Nazi ideology and personnel following the Second World War. It was carried out by removing those who had been Nazi Party or SS members from positions of power and influence, by disbanding the organisations associated with Nazism, and by trying prominent Nazis for war crimes. The program was hugely unpopular in West Germany and was opposed by the new government of Konrad Adenauer. In 1951, several laws were passed granting amnesties and ending denazification. As a result, many people with a former Nazi past ended up again in the political apparatus of West Germany. Between 1951 and 1953, there was even an effort by a clandestine group of former Nazi functionaries, known as the Naumann Circle, to infiltrate the Free Democratic Party (FDP) in order to lay the groundwork for an eventual return to power. Although this effort was exposed and disrupted, many former Nazis still attained positions of power and influence in the political system. West German President (1974–1979) Walter Scheel and Chancellor (1966–1969) Kurt Georg Kiesinger were both former members of the Nazi Party. Konrad Adenauer's State Secretary Hans Globke had played a major role in drafting the antisemitic Nuremberg Race Laws in Nazi Germany. In 1957, 77% of the West German Ministry of Justice's senior officials were former Nazi Party members.
Delirium and depression can be common among individuals and are important to rule out. Psychological tests for depression are used, since depression can either be concurrent with AD (see Depression of Alzheimer disease), an early sign of cognitive impairment, or even the cause. Due to low accuracy, the C-PIB-PET scan is not recommended as an early diagnostic tool or for predicting the development of AD when people show signs of mild cognitive impairment (MCI). The use of 18F-FDG PET scans, as a single test, to identify people who may develop Alzheimer's disease is not supported by evidence. In 2025, the US FDA approved a blood test, Fujirebio Diagnostics' Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, for the early detection of amyloid plaques associated with AD in adults aged 55 years and older who are exhibiting signs and symptoms of the disease. In 2026, the FDA approved the PrecivityAD2 blood test, which measures the ratios of amyloid beta 42, amyloid beta 40, p-tau217 and total tau217, for those as young as 40.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.